Mohini Ranganathan
Overview
Explore the profile of Mohini Ranganathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
2129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn L, Aquino J, Bassir Nia A, et al.
Psychopharmacology (Berl)
. 2024 Jun;
241(10):2145-2155.
PMID: 38832949
Rationale: Recent reports have shown increased cannabis use among women, leading to growing concerns about cannabis use disorder (CUD). While there is preclinical evidence suggesting biological sex influences cannabinoid effects,...
2.
Pfeiffer P, Geller J, Ganoczy D, Jagusch J, Carty J, Festin F, et al.
J Clin Psychiatry
. 2024 Jan;
85(1).
PMID: 38206011
Intravenous (IV) ketamine is effective for reducing symptoms of major depressive disorder in short-term clinical trials; this study characterized clinical outcomes of repeated infusions in routine clinical practice and the...
3.
Mohammad Aghaei A, Urban Spillane L, Pittman B, Flynn L, Aquino J, Bassir Nia A, et al.
medRxiv
. 2023 Dec;
PMID: 38077095
Rationale: Recent reports have shown increased cannabis use among women, leading to growing concerns about cannabis use disorder (CUD). Some evidence suggests a faster progression to addiction in women, known...
4.
Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, et al.
Addict Biol
. 2023 Aug;
28(9):e13317.
PMID: 37644897
The opioid and cannabinoid receptor systems are inextricably linked-overlapping at the anatomical, functional and behavioural levels. Preclinical studies have reported that cannabinoid and opioid agonists produce synergistic antinociceptive effects. Still,...
5.
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, et al.
Biol Psychiatry Glob Open Sci
. 2023 Jul;
3(3):340-350.
PMID: 37519466
The phenotype of schizophrenia, regardless of etiology, represents the most studied psychotic disorder with respect to neurobiology and distinct phases of illness. The early phase of illness represents a unique...
6.
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, et al.
Schizophr Res
. 2023 May;
256:36-43.
PMID: 37141764
N-methyl-d-aspartate glutamate receptor (NMDAR) hypofunction is implicated in the impaired neuroplasticity and cognitive impairments associated with schizophrenia (CIAS). We hypothesized that enhancing NMDAR function by inhibiting the glycine transporter-1 (GLYT1)...
7.
Schnakenberg Martin A, Flynn L, Sefik E, Luddy C, Cortes-Briones J, Skosnik P, et al.
Psychopharmacology (Berl)
. 2023 Apr;
240(6):1235-1246.
PMID: 37045988
Rationale: Drug- and alcohol-related motor vehicle accidents are a leading cause of morbidity and mortality worldwide. Compared to alcohol, less is known about the effects of cannabis on driving and...
8.
Ganesh S, Lam T, Garcia-Milian R, DSouza D, Nairn A, Elgert K, et al.
World J Biol Psychiatry
. 2023 Mar;
24(7):603-613.
PMID: 36994633
Background: Rates of Cannabis Use Disorder (CUD) are highest amongst young adults. Paucity of brain tissue samples limits the ability to examine the molecular basis of cannabis related neuropathology. Proteomic...
9.
Radhakrishnan R, Worhunsky P, Zheng M, Najafzadeh S, Gallezot J, Planeta B, et al.
Neuroimage
. 2022 Oct;
264:119674.
PMID: 36243269
Brain cannabinoid 1 receptors (CB1Rs) contribute importantly to the regulation of autonomic tone, appetite, mood and cognition. Inconsistent results have been reported from positron emission tomography (PET) studies using different...
10.
Oslin D, Lynch K, Shih M, Ingram E, Wray L, Chapman S, et al.
JAMA
. 2022 Jul;
328(2):151-161.
PMID: 35819423
Importance: Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment. Objective: To determine whether...